Moxetumomab Pasudotox: First Global Approval
Sign Up to like & getrecommendations! Published in 2018 at "Drugs"
DOI: 10.1007/s40265-018-1000-9
Abstract: Moxetumomab pasudotox-tdfk (LUMOXITI™), an anti CD22 recombinant immunotoxin, has been developed by MedImmune and its parent company AstraZeneca for the treatment of hairy cell leukaemia. The product, discovered at the National Cancer Institute, is an… read more here.
Keywords: pasudotox; approval; cell leukaemia; moxetumomab pasudotox ... See more keywords
Deamidation in Moxetumomab Pasudotox Leading to Conformational Change and Immunotoxin Activity Loss.
Sign Up to like & getrecommendations! Published in 2020 at "Journal of pharmaceutical sciences"
DOI: 10.1016/j.xphs.2020.06.002
Abstract: Asparagine deamidation is a common posttranslational modification in which asparagine (Asn) is converted to aspartic acid or isoaspartic acid. By introducing a negative charge, deamidation could potentially impact the binding interface and biological activities of… read more here.
Keywords: deamidation; activity; moxetumomab pasudotox; immunotoxin ... See more keywords
Moxetumomab pasudotox in relapsed/refractory hairy cell leukemia
Sign Up to like & getrecommendations! Published in 2018 at "Leukemia"
DOI: 10.1038/s41375-018-0210-1
Abstract: This is a pivotal, multicenter, open-label study of moxetumomab pasudotox, a recombinant CD22-targeting immunotoxin, in hairy cell leukemia (HCL), a rare B cell malignancy with high CD22 expression. The study enrolled patients with relapsed/refractory HCL… read more here.
Keywords: cell; response; moxetumomab pasudotox; cell leukemia ... See more keywords
A phase I study of moxetumomab pasudotox in adults with relapsed or refractory B‐cell acute lymphoblastic leukaemia
Sign Up to like & getrecommendations! Published in 2018 at "British Journal of Haematology"
DOI: 10.1111/bjh.14806
Abstract: Tolerogenic signals delivered by dendritic cells to T cells through a galectin-1-driven immunoregulatory circuit involving interleukin 27 and interleukin 10. Nature Immunology, 10, 981–991. James, P.D., Lillicrap, D. & Mannucci, P.M. (2013) Alloantibodies in von… read more here.
Keywords: moxetumomab pasudotox; study moxetumomab; study; von willebrand ... See more keywords
Phase 1 study of the anti-CD22 immunotoxin moxetumomab pasudotox for childhood acute lymphoblastic leukemia.
Sign Up to like & getrecommendations! Published in 2017 at "Blood"
DOI: 10.1182/blood-2017-02-749101
Abstract: Novel therapies are needed to overcome chemotherapy resistance for children with relapsed/refractory acute lymphoblastic leukemia (ALL). Moxetumomab pasudotox is a recombinant anti-CD22 immunotoxin. A multicenter phase 1 study was conducted to determine the maximum-tolerated cumulative… read more here.
Keywords: phase; moxetumomab pasudotox; lymphoblastic leukemia; acute lymphoblastic ... See more keywords